4.6 Article

Cytomegalovirus after kidney transplantation in 2020: moving towards personalized prevention

期刊

NEPHROLOGY DIALYSIS TRANSPLANTATION
卷 37, 期 5, 页码 810-816

出版社

OXFORD UNIV PRESS
DOI: 10.1093/ndt/gfaa249

关键词

cytomegalovirus; kidney transplantation; mTOR; prophylaxis; valganciclovir

向作者/读者索取更多资源

CMV-related complications after kidney transplantation present a significant challenge. Tailoring preventive strategies based on individual patient risk levels can improve outcomes. CMV-specific T-cell assays can help predict CMV risk pre-transplantation. Immunosuppressive regimens including mammalian target of rapamycin inhibitors can reduce CMV risk. New antiviral agents and adoptive T-cell therapy hold promise for future treatment options.
Cytomegalovirus (CMV)-related complications after kidney transplantation remain a substantial challenge. Rather than applying one preventive strategy to all at-risk patients, we can now adapt our strategy at the individual patient level. Antiviral prophylaxis or a strict pre-emptive strategy may be optimal for patients at the highest risk for CMV, while patients at lower risk may benefit particularly from pre-emptive monitoring and the administration of therapy only if needed. CMV-specific T-cell assays may be useful for further refining the pre-transplant determination of CMV risk, and for guiding decisions about antiviral therapy need or duration. An immunosuppressive regimen including a mammalian target of rapamycin inhibitor reduces CMV risk and may thus be an attractive option in some patients. New antiviral agents may further expand our therapeutic arsenal in the near future, and the prospects of CMV vaccination and adoptive T-cell therapy appear to be on the horizon.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据